<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Intern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Intern. Med</journal-id>
      <journal-id journal-id-type="doi">10.2169/internalmedicine.55.7117</journal-id>
      <journal-title-group>
        <journal-title>Internal Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0918-2918</issn>
      <issn pub-type="epub">1349-7235</issn>
      <publisher>
        <publisher-name>The Japanese Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27803409</article-id>
      <article-id pub-id-type="pmc">5140864</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary Mediastinal Large B-cell Lymphoma Exhibiting Endobronchial Involvement</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Shimada</surname>
            <given-names>Midori</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fukuda</surname>
            <given-names>Minoru</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Horio</surname>
            <given-names>Kensuke</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suyama</surname>
            <given-names>Takayuki</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kitazaki</surname>
            <given-names>Takeshi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hashiguchi</surname>
            <given-names>Kohji</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fukuda</surname>
            <given-names>Masaaki</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shigematsu</surname>
            <given-names>Kazuto</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakamura</surname>
            <given-names>Yoichi</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Honda</surname>
            <given-names>Takuya</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ashizawa</surname>
            <given-names>Kazuto</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mukae</surname>
            <given-names>Hiroshi</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">6</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Japan</aff>
        <aff id="aff2"><label>2</label>Clinical Oncology Center, Nagasaki University Hospital, Japan</aff>
        <aff id="aff3"><label>3</label>Department of Hematology Medicine, Japanese Red Cross Nagasaki Genbaku Hospital, Japan</aff>
        <aff id="aff4"><label>4</label>Department of Pathology, Japanese Red Cross Nagasaki Genbaku Hospital, Japan</aff>
        <aff id="aff5"><label>5</label>Department of Respiratory Medicine, Tochigi Cancer Center, Japan</aff>
        <aff id="aff6"><label>6</label>Second Department of Internal Medicine, Nagasaki University Hospital, Japan</aff>
      </contrib-group>
      <author-notes>
        <fn>
          <p>Correspondence to Dr.&#x3000;Minoru Fukuda, <email>mifukuda258@nifty.com</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>1</day>
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <volume>55</volume>
      <issue>21</issue>
      <fpage>3147</fpage>
      <lpage>3150</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>1</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p><!--CREATIVE COMMONS-->The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Primary mediastinal large B-cell lymphoma (PMLBCL) is one of the subtypes of diffuse large B-cell lymphoma. We experienced a rare case of PMLBCL that exhibited endobronchial involvement. A 33-year-old Japanese female with the chief complaints of epigastralgia, back pain, and nausea visited a primary care hospital. Computed tomography of the chest and abdomen demonstrated a bulky mass in the left anterior mediastinum, multiple pulmonary nodules, axillary lymph node swelling, and a pancreatic tumor. Fiberoptic bronchoscopy showed a white-tinged irregularly shaped endobronchial tumor accompanied by capillary vessel dilation in the left upper lobar bronchus. Taken together, these findings resulted in a diagnosis of PMLBCL. </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>primary mediastinal large B-cell lymphoma</kwd>
        <kwd>endobronchial involvement</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Primary mediastinal large B-cell lymphoma (PMLBCL) is one of the subtypes of diffuse large B-cell lymphoma (DLBCL), which is derived from B cells of thymic origin (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B4" ref-type="bibr">4</xref>). It usually occurs in young women and presents as a rapidly enlarging anterior mediastinal mass. The most common symptoms of the disease including coughing, chest pain, dyspnea, and venous obstruction. Recently, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been reported to be useful for investigating cases of suspected lymphoma (<xref rid="B5" ref-type="bibr">5</xref>); however, PMLBCL are rarely directly observable during endoscopy. We herein present the case of a young woman with PMLBCL, in which an endobronchial tumor was directly observed and diagnosed by bronchoscopy.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 33-year-old Japanese female with the chief complaints of epigastralgia, back pain, and nausea visited a primary care hospital. In addition to her chief complaints, the patient had also been suffering from a cough, general malaise, and loss of appetite for a month. Computed tomography (CT) of the chest and abdomen demonstrated a bulky mass measuring 10 cm in diameter in the left anterior mediastinum, multiple pulmonary nodules (measuring up to 3 cm in diameter), axillary lymph node swelling (<xref ref-type="fig" rid="g001">Fig. 1</xref>), and a pancreatic tumor. She was therefore admitted to our hospital for further examination and symptom management. The patient's physical findings at the time of the first medical examination were as follows: pulse rate: 72/min (regular pulse), blood pressure: 128/80 mmHg, body temperature: 36.7&#x2103;, and oxygen saturation (SpO<sub>2</sub>): 97% in room air. The patient exhibited no external abnormalities. Normal findings were obtained during auscultatory examinations of the patient's chest and heart. Serological tests revealed the following findings: C-reactive protein level: 5.24 mg/dL, lactate dehydrogenase level: 979 IU/L, fibrinogen level: 509 mg/dL, d-dimer level: 1.8 &#x3BC;g/mL, and fibrin degradation product level: 9.19 &#x3BC;g/mL. Tumor marker tests detected elevated soluble interleukin-2 receptor (1,660 U/mL) levels.</p>
      <fig id="g001" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Computed tomographic images of the chest with the mediastinal (A, B) and lung window settings (C) obtained at onset.</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3147-g001"/>
      </fig>
      <p>Fiberoptic bronchoscopy revealed a white-tinged irregularly shaped endobronchial tumor accompanied by capillary vessel dilatation in the left upper lobar bronchus, which was found to be almost completely obstructed (<xref ref-type="fig" rid="g002">Fig. 2</xref>). A histological examination detected bright cell bodies of various sizes and tumor cells with naked nuclei. The cells exhibited a proliferative and invasive activity, but they had not yet formed a well-defined structure (<xref ref-type="fig" rid="g003">Fig. 3</xref>), and an immunohistochemical examination showed the tumor cells to be negative for CD3 (<xref ref-type="fig" rid="g004">Fig. 4A</xref>), CD56, synaptophysin, and AE1/AE3 (data not shown), while they were positive for CD20 (<xref ref-type="fig" rid="g004">Fig. 4B</xref>) and leukocyte common antigen. Histologically, the tumor was diagnosed to be diffuse large B-cell lymphoma, and as the primary tumor developed in the mediastinum we finally diagnosed the patient with PMLBCL. The patient was treated with R-CHASE (rituximab, cyclophosphamide, high-dose arabinoside, steroids, and etoposide) chemotherapy and achieved a tumor response (<xref ref-type="fig" rid="g005">Fig. 5</xref>). Tumor marker tests also detected normalized soluble interleukin-2 receptor (314 U/mL) levels.</p>
      <fig id="g002" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Fiberoptic bronchoscopy findings of the lingular segment of the left lung.</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3147-g002"/>
      </fig>
      <fig id="g003" orientation="portrait" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>Pathological features observed during Hematoxylin and Eosin staining.
</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3147-g003"/>
      </fig>
      <fig id="g004" orientation="portrait" position="float">
        <label>Figure 4.</label>
        <caption>
          <p>Pathological features observed during an immunohistochemical examination of the CD3 (A) and CD20 (B) expression.</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3147-g004"/>
      </fig>
      <fig id="g005" orientation="portrait" position="float">
        <label>Figure 5.</label>
        <caption>
          <p>Computed tomographic images of the chest with the mediastinal (A) and lung window settings (B) obtained after one cycle of R-CHASE treatment.</p>
        </caption>
        <graphic xlink:href="1349-7235-55-3147-g005"/>
      </fig>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>PMLBCL was first described in the early 1980s (<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>) and is one of the subtypes of DLBCL. It constitutes from 2-3% of all non-Hodgkin's lymphomas and from 6-10% of all DLBCL (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B4" ref-type="bibr">4</xref>). No particular risk factors for this disease have been identified. It commonly presents as a bulky lesion in the anterior-superior mediastinum and is associated with symptoms related to local invasion or compression, including dyspnea, coughing, chest pain, and dysphagia (<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>). It tends to occur in younger adults and exhibits a female predominance (median age: 30 to 40 years; male to female ratio: 1:2). In the present case, the patient was in her 30s and presented with a bulky mediastinal mass and anterior and back pain, coughing, dyspnea, nausea, and fatigue.</p>
      <p>Fluoroscopy- or computed tomography-guided needle biopsies often yield sufficient amounts of tissue specimens for a diagnostic workup and to prepare paraffin-fixed tissue sections for histological examinations and immunohistochemical analyses (<xref rid="B4" ref-type="bibr">4</xref>). Recently, EBUS-TBNA was reported to be useful for diagnosing primary mediastinal malignant lymphoma (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>). In the present case, fiberoptic bronchoscopy detected endobronchial involvement, and we were able to obtain tumor samples from the lingular segment of the left lung and thus diagnose PMLBCL without EBUS-TBNA. The development of extrapulmonary malignant tumors in the endobronchial region is uncommon and is mainly associated with colon, breast, and kidney cancer (<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>). Although lymphomas often occur in the lungs, endobronchial lymphoma is extremely rare, and very few of the cases reported in the literature were diagnosed by bronchoscopy. For example, no endobronchial lesions were detected in a study of 55 patients who were diagnosed with non-Hodgkin's lymphoma (<xref rid="B13" ref-type="bibr">13</xref>), and only one endobronchial lesion was seen among 93 patients with primary lung lymphoma (<xref rid="B14" ref-type="bibr">14</xref>). Endobronchial lymphoma can be categorized into two types. The first involves the accumulation of diffuse submucosal infiltrates due to the lymphangitic or hematogenous spread of systemic lymphoma such as colon, breast and lung cancer. The other type, to which the present case belongs, involves the development of a localized nodule in the airway due to the direct spread of lymphoma from the neighboring lymph nodes or the <italic>de novo</italic> development of such a lesion from bronchus-associated lymphoid tissue. Bronchoscopy or EBUS-TBNA should be performed to screen for endobronchial involvement in cases involving a mediastinal mass and multiple pulmonary nodules.</p>
      <p>The optimum chemotherapy regimen for PMLBCL has not yet been established, and several approaches from first-generation cyclophosphamide (CHOP)-like regimens to third-generation multi-drug chemotherapy regimens have been tried (<xref rid="B15" ref-type="bibr">15</xref>). In the present case, the patient was treated with the R-CHASE regimen and achieved a partial response. R-CHASE is a combination chemotherapy regimen in which rituximab is added to the CHASE regimen (cyclophosphamide, cytosine arabinoside, etoposide, and dexamethasone) developed by the Aichi Cancer Center (<xref rid="B16" ref-type="bibr">16</xref>). In a pilot phase I/II study of patients with refractory or relapsed lymphoma, the CHASE regimen achieved a complete response rate of 71.4% in 14 patients. Recently, Dunleavy et al. administered the dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) regimen in combination with filgrastim (without radiotherapy) and achieved an event-free survival rate of 93% and an overall survival rate of 97% during a median follow-up period of 5 years (<xref rid="B17" ref-type="bibr">17</xref>). The latter approach might thus become the new standard treatment for PMLBCL.</p>
      <p>In conclusion, we herein reported a case of PMLBCL exhibiting endobronchial involvement, in which the disease was diagnosed by bronchoscopy and treated with R-CHASE. Although endobronchial PMLBCL lesions are rare, we consider that bronchoscopy should be promptly performed when a mediastinal mass and pulmonary lesions are observed on CT.</p>
    </sec>
    <sec>
      <title>The authors state that they have no Conflict of Interest (COI).</title>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cazals-Hatem</surname><given-names>D</given-names></name>, <name><surname>Repage</surname><given-names>E</given-names></name>, <name><surname>Brice</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Primary mediastinal large B-cell lymphoma: a clinocopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphoma, a GELA study</article-title>. <source>Am J Surg Pathol</source>
<volume>20</volume>: <fpage>877</fpage>-<lpage>888</lpage>, <year>1996</year>.<pub-id pub-id-type="pmid">8669537</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barth</surname><given-names>TF</given-names></name>, <name><surname>Leithauser</surname><given-names>F</given-names></name>, <name><surname>Joos</surname><given-names>S</given-names></name>, <name><surname>Bentz</surname><given-names>M</given-names></name>, <name><surname>Moller</surname><given-names>P</given-names></name></person-group>
<article-title>Mediastinal (thymic) large B-cell lymphoma: where do we stand?</article-title>
<source>Lancet Oncol</source>
<volume>3</volume>: <fpage>229</fpage>-<lpage>234</lpage>, <year>2002</year>.<pub-id pub-id-type="pmid">12067685</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>E</given-names></name>, <name><surname>Stoecker</surname><given-names>M</given-names></name></person-group>
<article-title>Primary mediastinal (thymic) large B-cell lymphoma with aberrant expression of CD3: a case report with review of the literature</article-title>. <source>Int J Hematol</source>
<volume>91</volume>: <fpage>509</fpage>-<lpage>515</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20131102</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hutchinson</surname><given-names>CB</given-names></name>, <name><surname>Wang</surname><given-names>E</given-names></name></person-group>
<article-title>Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma</article-title>. <source>Arch Pathol Lab Med</source>
<volume>135</volume>: <fpage>394</fpage>-<lpage>398</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">21366467</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>MP</given-names></name>, <name><surname>Jimenez</surname><given-names>CA</given-names></name>, <name><surname>Bruzzi</surname><given-names>JF</given-names></name>, <etal>et al</etal></person-group>
<article-title>Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma</article-title>. <source>Thorax</source>
<volume>63</volume>: <fpage>360</fpage>-<lpage>365</lpage>, <year>2008</year>.<pub-id pub-id-type="pmid">17965071</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Levitt</surname><given-names>LJ</given-names></name>, <name><surname>Aisenberg</surname><given-names>AC</given-names></name>, <name><surname>Harris</surname><given-names>NL</given-names></name>, <name><surname>Linggood</surname><given-names>RM</given-names></name>, <name><surname>Poppema</surname><given-names>S</given-names></name></person-group>
<article-title>Primary non-Hodgkin's lymphoma of the mediastinum</article-title>. <source>Cancer</source>
<volume>50</volume>: <fpage>2486</fpage>-<lpage>2492</lpage>, <year>1982</year>.<pub-id pub-id-type="pmid">7139540</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trump</surname><given-names>DL</given-names></name>, <name><surname>Mann</surname><given-names>RB</given-names></name></person-group>
<article-title>Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement</article-title>. <source>Cancer</source>
<volume>50</volume>: <fpage>277</fpage>-<lpage>282</lpage>, <year>1982</year>.<pub-id pub-id-type="pmid">7044520</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lazzarino</surname><given-names>M</given-names></name>, <name><surname>Orlandi</surname><given-names>E</given-names></name>, <name><surname>Paulli</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients</article-title>. <source>J Clin Oncol</source>
<volume>15</volume>: <fpage>1646</fpage>-<lpage>1653</lpage>, <year>1997</year>.<pub-id pub-id-type="pmid">9193365</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinfort</surname><given-names>DP</given-names></name>, <name><surname>Conron</surname><given-names>M</given-names></name>, <name><surname>Tsui</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Endobronchial ultrasound-guided transbronchial needle aspiration for the evaluation of suspected lymphoma</article-title>. <source>J Thorac Onchol</source>
<volume>5</volume>: <fpage>804</fpage>-<lpage>809</lpage>, <year>2010</year>.</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inoue</surname><given-names>M</given-names></name>, <name><surname>Nakajima</surname><given-names>T</given-names></name>, <name><surname>Tsujimura</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Mediastinal follicular lymphoma diagnosed with multidirectional analysis using tissue samples obtained by EBUS-TBNA</article-title>. <source>Intern Med</source>
<volume>49</volume>: <fpage>2147</fpage>-<lpage>2149</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20930445</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Katsimbri</surname><given-names>PP</given-names></name>, <name><surname>Bamias</surname><given-names>AT</given-names></name>, <name><surname>Froudarakis</surname><given-names>ME</given-names></name>, <name><surname>Peponis</surname><given-names>IA</given-names></name>, <name><surname>Constantopoulos</surname><given-names>SH</given-names></name>, <name><surname>Pavlidis</surname><given-names>NA</given-names></name></person-group>
<article-title>Endobronchial metastases secondary to solid tumors: report of eight cases and review of the literature</article-title>. <source>Lung Cancer</source>
<volume>28</volume>: <fpage>163</fpage>-<lpage>170</lpage>, <year>2000</year>.<pub-id pub-id-type="pmid">10717334</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kiryu</surname><given-names>T</given-names></name>, <name><surname>Hoshi</surname><given-names>H</given-names></name>, <name><surname>Matsui</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Endotracheal/endobronchial metastases: clinicopathologic study with special reference to developmental modes</article-title>. <source>Chest</source>
<volume>119</volume>: <fpage>768</fpage>-<lpage>775</lpage>, <year>2001</year>.<pub-id pub-id-type="pmid">11243955</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vieta</surname><given-names>JO</given-names></name>, <name><surname>Craver</surname><given-names>LF</given-names></name></person-group>
<article-title>Intrathoracic manifestations of the lymphomatoid diseases</article-title>. <source>Radiology</source>
<volume>37</volume>: <fpage>133</fpage>-<lpage>159</lpage>, <year>1941</year>.</mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pappaioannau</surname><given-names>NA</given-names></name>, <name><surname>Watson</surname><given-names>WI</given-names></name></person-group>
<article-title>Primary lymphoma of the lung; an appraisal of its natural history and a comparison with other localized lymphoma</article-title>. <source>J Thorac Cardiovasc Surg</source>
<volume>49</volume>: <fpage>373</fpage>-<lpage>387</lpage>, <year>1965</year>.<pub-id pub-id-type="pmid">14265953</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martelli</surname><given-names>M</given-names></name>, <name><surname>Ferreri</surname><given-names>AJ</given-names></name>, <name><surname>Johnson</surname><given-names>P</given-names></name></person-group>
<article-title>Primary mediastinal large B-cell lymphoma</article-title>. <source>Crit Rev Oncol Hematol</source>
<volume>68</volume>: <fpage>256</fpage>-<lpage>263</lpage>, <year>2008</year>.<pub-id pub-id-type="pmid">18774728</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ogura</surname><given-names>M</given-names></name>, <name><surname>Kagami</surname><given-names>Y</given-names></name>, <name><surname>Taji</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Pilot phase I/II study of new salvage therapy (CHASE) for refractory or relapsed malignant lymphoma</article-title>. <source>Int J Hematol</source>
<volume>77</volume>: <fpage>503</fpage>-<lpage>511</lpage>, <year>2003</year>.<pub-id pub-id-type="pmid">12841390</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dunleavy</surname><given-names>K</given-names></name>, <name><surname>Pittaluga</surname><given-names>S</given-names></name>, <name><surname>Maeda</surname><given-names>LS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Dose-adjusted EPOCH-Rituximab therapy in primary mediastinal B-cell lymphoma</article-title>. <source>N Engl J Med</source>
<volume>368</volume>: <fpage>1408</fpage>-<lpage>1416</lpage>, <year>2013</year>.<pub-id pub-id-type="pmid">23574119</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
